BRPI1007968A2 - derivado de anel hetero - Google Patents
derivado de anel heteroInfo
- Publication number
- BRPI1007968A2 BRPI1007968A2 BRPI1007968A BRPI1007968A BRPI1007968A2 BR PI1007968 A2 BRPI1007968 A2 BR PI1007968A2 BR PI1007968 A BRPI1007968 A BR PI1007968A BR PI1007968 A BRPI1007968 A BR PI1007968A BR PI1007968 A2 BRPI1007968 A2 BR PI1007968A2
- Authority
- BR
- Brazil
- Prior art keywords
- ring derivative
- straight ring
- straight
- derivative
- ring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009029759 | 2009-02-12 | ||
| PCT/JP2010/051910 WO2010092962A1 (ja) | 2009-02-12 | 2010-02-10 | へテロ環誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1007968A2 true BRPI1007968A2 (pt) | 2016-10-04 |
Family
ID=42561804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007968A BRPI1007968A2 (pt) | 2009-02-12 | 2010-02-10 | derivado de anel hetero |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120165309A1 (pt) |
| EP (1) | EP2397479A4 (pt) |
| JP (1) | JPWO2010092962A1 (pt) |
| KR (1) | KR20110120286A (pt) |
| CN (1) | CN102317282A (pt) |
| AU (1) | AU2010214440A1 (pt) |
| BR (1) | BRPI1007968A2 (pt) |
| CA (1) | CA2755935A1 (pt) |
| IL (1) | IL214568A0 (pt) |
| MX (1) | MX2011008444A (pt) |
| RU (1) | RU2011137399A (pt) |
| TW (1) | TW201033194A (pt) |
| WO (1) | WO2010092962A1 (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| TW201038567A (en) * | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2604601B1 (en) * | 2010-08-10 | 2016-02-24 | Astellas Pharma Inc. | Hetero ring compound |
| WO2012101654A2 (en) * | 2011-01-25 | 2012-08-02 | Sphaera Pharma Pvt. Ltd | Novel triazine compounds |
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| AU2012236722A1 (en) * | 2011-03-28 | 2013-10-17 | Mei Pharma, Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| WO2012135166A1 (en) * | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| EP2714698B1 (en) * | 2011-05-31 | 2016-11-09 | Merck Patent GmbH | Compounds containing hydrido-tricyano-borate anions |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| IN2014DN07014A (pt) * | 2012-02-20 | 2015-04-10 | Rhodia Operations | |
| US9340549B2 (en) | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| NZ746607A (en) | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| EA034866B1 (ru) | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) * | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2016058544A1 (en) * | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| TWI726861B (zh) * | 2015-01-23 | 2021-05-11 | 英商葛蘭素史克智慧財產發展有限公司 | 吡唑并-嘧啶化合物、其鹽及其用途 |
| CN104693075B (zh) * | 2015-02-13 | 2016-05-11 | 程涛 | p18小分子抑制剂及在人造血干细胞体外扩增中的用途 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP6947651B2 (ja) * | 2015-06-26 | 2021-10-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ４，６−ピリミジニレン誘導体およびこれらの使用 |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| IL292938A (en) | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| AU2017363307B2 (en) | 2016-11-22 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
| JP6984239B2 (ja) * | 2017-08-29 | 2021-12-17 | 東洋インキＳｃホールディングス株式会社 | キサンテン化合物の製造方法 |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CA3116339A1 (en) | 2018-10-22 | 2020-04-30 | Cadent Therapeutics, Inc. | Crystalline forms of potassium channel modulators |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| KR20230069126A (ko) * | 2020-09-15 | 2023-05-18 | 미쓰비시 타나베 파마 코퍼레이션 | 트리아진 화합물의 염, 그 결정형 및 제조 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1129597C (zh) | 1997-07-24 | 2003-12-03 | 全药工业株式会社 | 杂环化合物和以其为有效成分的抗肿瘤剂 |
| WO2000043385A1 (en) | 1999-01-25 | 2000-07-27 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agents containing the same as the active ingredient |
| GEP20084317B (en) | 2000-04-25 | 2008-02-25 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| CA2503451C (en) | 2002-10-25 | 2011-07-12 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compounds and antitumor agent comprising the same as effective component |
| JP4733021B2 (ja) | 2004-03-31 | 2011-07-27 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| CN101137382B (zh) | 2005-03-11 | 2012-11-21 | 全药工业株式会社 | 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂 |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB0612630D0 (en) | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
| CN101535296A (zh) | 2006-09-14 | 2009-09-16 | 阿斯利康(瑞典)有限公司 | 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物 |
| EP2064203A1 (en) * | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| CN101595103A (zh) | 2006-09-14 | 2009-12-02 | 阿斯利康(瑞典)有限公司 | 嘧啶衍生物 |
| WO2008032041A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
| WO2008032077A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032027A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
| JP2010503648A (ja) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体 |
| WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
| JP2010523639A (ja) | 2007-04-12 | 2010-07-15 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬化合物 |
| JP2011515462A (ja) * | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
-
2010
- 2010-02-10 JP JP2010550527A patent/JPWO2010092962A1/ja not_active Withdrawn
- 2010-02-10 US US13/201,072 patent/US20120165309A1/en not_active Abandoned
- 2010-02-10 EP EP10741239A patent/EP2397479A4/en not_active Withdrawn
- 2010-02-10 RU RU2011137399/04A patent/RU2011137399A/ru unknown
- 2010-02-10 CN CN2010800078415A patent/CN102317282A/zh active Pending
- 2010-02-10 AU AU2010214440A patent/AU2010214440A1/en not_active Abandoned
- 2010-02-10 KR KR1020117018692A patent/KR20110120286A/ko not_active Withdrawn
- 2010-02-10 CA CA2755935A patent/CA2755935A1/en not_active Abandoned
- 2010-02-10 MX MX2011008444A patent/MX2011008444A/es active IP Right Grant
- 2010-02-10 BR BRPI1007968A patent/BRPI1007968A2/pt not_active IP Right Cessation
- 2010-02-10 WO PCT/JP2010/051910 patent/WO2010092962A1/ja not_active Ceased
- 2010-02-12 TW TW099104688A patent/TW201033194A/zh unknown
-
2011
- 2011-08-09 IL IL214568A patent/IL214568A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102317282A (zh) | 2012-01-11 |
| JPWO2010092962A1 (ja) | 2012-08-16 |
| EP2397479A1 (en) | 2011-12-21 |
| KR20110120286A (ko) | 2011-11-03 |
| TW201033194A (en) | 2010-09-16 |
| AU2010214440A1 (en) | 2011-09-01 |
| MX2011008444A (es) | 2011-09-06 |
| WO2010092962A1 (ja) | 2010-08-19 |
| CA2755935A1 (en) | 2010-08-19 |
| EP2397479A4 (en) | 2012-08-01 |
| US20120165309A1 (en) | 2012-06-28 |
| IL214568A0 (en) | 2011-09-27 |
| RU2011137399A (ru) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007968A2 (pt) | derivado de anel hetero | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| EP2433940A4 (en) | SPIROIMIDAZOLONDERIVAT | |
| EP2444400A4 (en) | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | |
| EP2462134A4 (en) | N1-sulfonyl-5-FLUORPYRIMIDINON DERIVATIVES | |
| EP2397480A4 (en) | DIAZEPINEDIONEDERIVATE | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| BRPI1012012A2 (pt) | anel de desvio de corrente | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| UY3955Q (es) | Carrocería | |
| BRPI1011468A2 (pt) | derivados condensados de pirrolipiridino | |
| BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| BR112012008108A2 (pt) | derivados de xantina substituídos | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| BR112012005503A2 (pt) | derivados de isoxazolidina | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| DK2387580T3 (da) | Deoxyactagardinderivater | |
| BRPI1007369A2 (pt) | derivados de di-hidroquinolinona | |
| EP2492266A4 (en) | 5-hydroxypyrimidine-4-carboxamide | |
| BR112012014770A2 (pt) | derivados de etinila | |
| BRPI1011416A2 (pt) | derivados de antraquinova novos | |
| BRPI1016192A2 (pt) | derivados de soxazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |